All In Biotech

Drug Trial Radar · NCT03813784

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

A Randomized, Open-label, Multi-center Phase III Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 885 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

885

Actual

Start

Mar 7, 2019

Primary completion

Jun 7, 2023

Study completion Jun 7, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by SHR-1210 plus apatinib versus capecitabine and oxaliplatin as first-line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Conditions

  • Gastric Cancer
  • GastroEsophageal Cancer

Interventions

  • SHR-1210Drug

    Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial

  • CapecitabineDrug

    1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.

  • OxaliplatinDrug

    130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.

  • ApatinibDrug

    250 mg administered as continuous oral once daily (QD) of each 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participantsTime frame: Up to 36 months after the first participant is randomized.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital, Peking University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.